For the three months and year ended December 31, 2024, the Company recorded a net loss attributable to common stockholders of ...

"It just ... it ruined his life. Ruined it. Completely ruined his life in 12 seconds," said Tim Kingerski, Ryan's father.

Q4 2024 Earnings Call Transcript February 19, 2025 Amicus Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Proposed legislation would clarify that direct primary care doctors are not part of the insurance industry and aren't ...

NeuroPace Inc. recently announced that it has entered into a stock purchase agreement with KCK Ltd. The agreement, dated February 13, 2025, outlines the Company’s commitment to repurchase all shares ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid. If approved, Dupixent would be the first and only targeted medicine to treat BP in ...

MU Health Care wrote in an email to patients who use Anthem Blue Cross Shield to apply for “Continuity of Care” in case the ...

Patient assistance programs (PAPs) emerged to help patients who lack health insurance or prescription drug coverage obtain ...

The Ballard Clinic sits across the street from the Greyhound bus station in the hollowed-out downtown of Jackson, Tenn., a small city about an hour from Memphis. After Dr. Thomas Ballard III took ...

Penn Highlands Healthcare is teaming up with IUP’s College of Osteopathic Medicine for a clinical training affiliation. “The ...

The objectives of this paper are to analyze the agreement of self-reported and general practitioner-reported chronic conditions among multimorbid patients in primary care, and to discover which ...

If the COMPANION trial is successful, Vicore intends to submit it for FDA approval as a medical device, in the hope of making it available to patients in 2024. If approved, Almee could form part ...